Recent Updates
Recently added Catalysts
CBLL Positive Sentiment

Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Key Takeaway: Ceribell, Inc. announced that CFO Scott Blumberg will participate in a fireside chat at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20, 2025. The event will be held in New York and will also feature a live and archived webcast. Ceribell specializes in advanced diagnostic solutions for neurological conditions.
Price reaction · baseline $11.56 (2025-11-06 close) · hit after-hours · clean, no other CBLL news in the window
day 0 close · peak
+3.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Ceribell is participating in a significant industry forum.
  • The company is focused on innovative solutions for neurological conditions.
  • The Ceribell System is FDA-cleared for detecting seizure activity.

Full Press Release Details

SUNNYVALE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Scott Blumberg, CFO, will participate in a fireside chat at the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York. The fireside chat will take place on Thursday, November 20, 2025, at 5:30 a.m. Pacific Standard Time / 8:30 a.m. Eastern Standard Time.

Event: Canaccord Genuity MedTech, Diagnostics and Digital Health & Services ForumDate: Thursday, November 20, 2025Time: 5:30 a.m. PST / 8:30 a.m. EST

A live and archived webcast of the presentation will be available in the "Investor Relations" section of the Ceribell website athttps://investors.ceribell.com/.
About CeriBell, Inc.Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for detecting suspected seizure activity and currently utilized in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visitwww.ceribell.comor follow the company onLinkedIn.

Investor ContactBrian Johnston or Laine MorganGilmartin GroupInvestors@ceribell.com

Media ContactBrian PricePress@ceribell.com

Frequently Asked Questions

When will Ceribell participate in the forum?

Ceribell will participate in the forum on November 20, 2025.

Who from Ceribell will speak at the event?

Scott Blumberg, the CFO of Ceribell, will speak at the event.

What is the focus of Ceribell's technology?

Ceribell focuses on transforming the diagnosis and management of neurological conditions.

Where is the Canaccord Genuity Forum being held?

The forum will be held in New York.

Last updated: Nov 6, 2025